Richard Miller, MD
Nephrology · Brookhaven, MSNPI 1053533406
Payments from drug & device makers
Across 440 payments — averaging $1754.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- OPKO Pharmaceuticals, LLC$281K
- CSL Behring$200K
- Merck$108K
- AstraZeneca$69K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$52K
- Vertex$39K
- plus $22K from 24 others
What the payments were for
- Travel & lodging$4,38542%
- Food & beverage$5,79556%
- Education$2512%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| OPKO Pharmaceuticals, LLC | 47 | $280,985 |
| CSL Behring | 102 | $200,369 |
| Merck | 15 | $107,664 |
| AstraZeneca | 54 | $69,320 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $52,265 |
| Vertex | 5 | $38,940 |
| GSK | 11 | $17,570 |
| Bayer | 45 | $821 |
| Boehringer Ingelheim International GmbH | 1 | $750 |
| Akebia Therapeutics Inc | 32 | $635 |
| Fresenius USA Marketing, Inc. | 17 | $340 |
| Vifor Pharma, Inc. | 22 | $337 |
| Aurinia Pharma U.S., Inc. | 12 | $279 |
| Otsuka America Pharmaceutical, Inc. | 9 | $221 |
| Amgen | 11 | $215 |
| Mallinckrodt Hospital Products Inc. | 7 | $190 |
| Calliditas Therapeutics US Inc. | 8 | $138 |
| Novartis | 4 | $119 |
| Boehringer Ingelheim | 7 | $116 |
| ANI Pharmaceuticals, Inc. | 6 | $113 |
| Scpharmaceuticals Inc. | 3 | $70 |
| Eisai Inc. | 4 | $56 |
| Travere Therapeutics, Inc. | 2 | $49 |
| Mallinckrodt Enterprises LLC | 3 | $48 |
| Ardelyx, Inc. | 2 | $46 |
| Lilly USA, LLC | 3 | $46 |
| Averitas Pharma Inc. | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Novo Nordisk | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$771,777 in reported general payments places this provider in the 95th percentile of 105 nephrology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 325 | $205,574 |
| JardianceEmpagliflozin | 254 | $167,713 |
| KerendiaFinerenone | 176 | $134,827 |
| VelphoroSucroferric Oxyhydroxide | 40 | $79,969 |
| XphozahTenapanor Hcl | 18 | $59,228 |
| RayaldeeCalcifediol | 34 | $40,141 |
| AuryxiaFerric Citrate | 17 | $25,800 |
| LokelmaSodium Zirconium Cyclosilicate | 11 | $8,087 |
| DapagliflozinDapagliflozin Propanediol | 14 | $6,443 |
| JanuviaSitagliptin Phosphate | 11 | $6,343 |
| Sevelamer Carbonate | 31 | $3,033 |
| Potassium Chloride | 104 | $2,103 |
| Nifedipine ErNifedipine | 65 | $1,043 |
| Calcium Acetate | 17 | $876 |
| Losartan Potassium | 118 | $801 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $69,320 | $213,661336 claims |
| Boehringer IngelheimJardiance | $116 | $167,713254 claims |
| BayerKerendia | $821 | $134,827176 claims |
| Fresenius USA Marketing, Inc.Velphoro | $340 | $79,96940 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $280,985 | $40,14134 claims |
| Akebia Therapeutics IncAuryxia | $635 | $25,80017 claims |
| MerckJanuvia | $107,664 | $6,34311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 105 nephrology providers in Mississippi.
Other nephrology in Brookhaven
- Paul DykesBrookhaven$344K
- Thomas WooldridgeTupelo$1.6M
- Angela RileyOxford$706K
- Mohit AhujaFlowood$427K
- Douglas LanierGulfport$422K
- Marcus BrittonTupelo$339K
- Thomas DunnColumbus$295K
- Kent KirchnerJackson$88K
- Erica HopkinsGulfport$70K
- Anita BasuJackson$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.